P65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Medicine & Life Sciences

• Adenocarcinoma 11%
• Adenocarcinoma of Lung 100%
• Agammaglobulinaemia Tyrosine Kinase 10%
• Biomarkers 4%
• Cause of Death 5%
• Cell Line 12%
• Cell Proliferation 4%
• Cell Survival 10%
• Cisplatin 6%
• Clinical Trials 4%
• Drug Therapy 16%
• Erlotinib Hydrochloride 9%
• Gefitinib 9%
• gemcitabine 8%
• Gentian Violet 9%
• Growth Inhibitors 9%
• Immunohistochemistry 4%
• Lung Neoplasms 11%
• Lymph Nodes 5%
• Mutation 4%
• Neoplasms 11%
• Non-Small Cell Lung Carcinoma 45%
• Non-Smokers 7%
• PCI 32765 10%
• Pemetrexed 9%
• Pharmaceutical Preparations 8%
• Protein Isoforms 5%
• Protein-Tyrosine Kinases 85%
• Psychological Inhibition 5%
• RN486 16%
• Smoking 5%
• Standard of Care 27%
• Therapeutics 4%
• Tumor Biomarkers 7%